Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,069.32 +58.72 (+1.17%) Dow
38,519.70 +279.72 (+0.73%) Nasdaq
15,686.15 +234.84 (+1.52%) Bitcoin USD
66,704.73 +58.86 (+0.09%) CMC Crypto 200
1,434.52 +19.76 (+1.40%)
Trevi Therapeutics, Inc. (TRVI)
| Previous close | 2.9400 |
| Open | 2.9500 |
| Bid | 3.0300 x 100 |
| Ask | 3.2000 x 100 |
| Day's range | 2.9500 - 3.1500 |
| 52-week range | 0.9700 - 4.0000 |
| Volume | |
| Avg. volume | 304,888 |
| Market cap | 213.777M |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2900 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.33 |
ZacksTrevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Trevi Therapeutics (TRVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
PR NewswireTrevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
ZacksWhy Trevi Therapeutics (TRVI) Stock Might be a Great Pick
Trevi Therapeutics (TRVI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
